Investor Relations
Cassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs.
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
May 05, 2022
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas , May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
Apr 25, 2022
- Q&A Session at Conference on Wednesday, April 27 th at 1:30PM Eastern - AUSTIN, Texas , April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the